Trade Report: Today, Bluebird Bio Inc. (BLUE) Given Outperform Rating at Leerink Swann

Today, Bluebird Bio Inc. (BLUE) Given Outperform Rating at Leerink Swann

Bluebird Bio Inc. (NASDAQ:BLUE)‘s stock had its “outperform” rating restated by analysts at Leerink Swann in a research note issued to investors on Monday. They presently have a $80.00 target price on the stock. Leerink Swann’s target price indicates a potential upside of 25.10% from the company’s current price.

A number of other research firms have also recently weighed in on BLUE. Jefferies Group set a $80.00 price objective on Bluebird Bio and gave the stock a “buy” rating in a research report on Saturday, October 15th. Maxim Group set a $85.00 price objective on Bluebird Bio and gave the stock a “buy” rating in a research report on Thursday, September 22nd. Wedbush reaffirmed an “outperform” rating and set a $117.00 price objective on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $95.00 price objective on shares of Bluebird Bio in a research report on Friday, November 4th. Finally, BTIG Research reaffirmed a “buy” rating and set a $83.00 price objective (up from $72.00) on shares of Bluebird Bio in a research report on Saturday, October 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $82.82.

Shares of Bluebird Bio (NASDAQ:BLUE) traded up 2.32% during mid-day trading on Monday, hitting $63.95. The stock had a trading volume of 505,529 shares. Bluebird Bio has a 52-week low of $35.37 and a 52-week high of $94.61. The company’s market cap is $2.39 billion. The stock has a 50 day moving average price of $56.23 and a 200-day moving average price of $52.68.

Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, November 2nd. The company reported ($2.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.59) by $0.48. The firm earned $1.55 million during the quarter, compared to analyst estimates of $1.82 million. Bluebird Bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%. The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same period last year, the company earned ($1.18) earnings per share. On average, equities analysts expect that Bluebird Bio will post ($7.05) earnings per share for the current fiscal year.

In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $67.00, for a total transaction of $27,872.00. Following the sale, the insider now owns 5,891 shares in the company, valued at approximately $394,697. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.50% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Wellington Management Group LLP bought a new stake in shares of Bluebird Bio during the first quarter worth approximately $51,095,000. BlackRock Inc. boosted its stake in shares of Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock worth $194,000 after buying an additional 3,533 shares during the period. California State Teachers Retirement System boosted its stake in shares of Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock worth $3,363,000 after buying an additional 1,682 shares during the period. Vanguard Group Inc. boosted its stake in shares of Bluebird Bio by 14.2% in the second quarter. Vanguard Group Inc. now owns 2,680,871 shares of the company’s stock worth $116,055,000 after buying an additional 333,396 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock worth $2,585,000 after buying an additional 5,700 shares during the period.

About Bluebird Bio

Related posts

Leave a Comment